Celgene International Sàrl, a wholly-owned subsidiary of Celgene Corp., received approval from the European Commission (EC) for Abraxane (paclitaxel formulated as albumin bound nanoparticles, or nab-paclitaxel) in combination with gemcitabine for first-line treatment of adult patients with metastatic adenocarcinoma of the pancreas, or metastatic pancreatic cancer. The EC decision was based on the results of MPACT (Metastatic Pancreatic Adenocarcinoma Clinical Trial), an open-label, Phase III, r...